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The prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA
(NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study
designed to assess the relationship between asthma biomarkers and disease-related health outcomes.
The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from
approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled
corticosteroid (500 mg of ﬂuticasone propionate or equivalent) and at least 1 second controller medi-
cation are to be included. In this real-world study, patients will be treated according to the investigator's
routine clinical practices and no treatment regimen will be implemented as part of the trial. At baseline
and again at 26 and 52 weeks, FEV1, FeNO, serum periostin, blood eosinophil count and serum IgE will be
measured. Asthma-related symptom and quality of life questionnaires will be administered at the visits
and during telephone interviews at Weeks 13 and 39. Data about medication use, asthma exacerbation
data, asthma-related healthcare utilization and events raising safety concerns will also be collected. This
study design, unique in both its scope and scale, will address fundamental unanswered questions
regarding asthma biomarkers and their interrelationship, as well as predict deviations in the course of
asthma in a real-world setting.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
What is the key question?
What is the relationship and prognostic value of asthma
biomarkers in severe asthma?
What is the bottom line?
This unique study is designed to address many open
questions related to biomarkers in a real-world asthma
setting.
Why read on?
To understand the potential prognostic value of biomarkers
in the management of your patients with severe asthma.(R. Buhl).
Ltd. This is an open access article uAsthma is a complex disease with marked heterogeneity in its
clinical course and response to treatment [1e3]. Recognizing and
understanding the heterogeneity of asthma is becoming increas-
ingly important as novel therapies are emerging and will soon be
available to target speciﬁc pathophysiological pathways [3e5].
Thus, there is a growing interest in understanding the natural
course and interaction of key asthma biomarkers and their asso-
ciation with meaningful clinical endpoints.
The step from the broad assessment of asthma symptoms, lung
function and response to medication toward an approach focused
on underlying cellular and molecular mechanisms involves a
growing number of potential biomarkers. To date, a host of bio-
markers related to different aspects of asthma pathophysiology and
clinical phenotypes have been identiﬁed and assessed, most oftennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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controlled intervention trials. However, the scientiﬁc interest in
these has not resulted in their widespread use in routine clinical
management of patients, e.g. monitoring disease progression,
predicting risk of exacerbation or evaluating response to therapy
[6,7]. A better understanding of asthma biomarkers such as frac-
tional exhaled nitric oxide (FeNO), blood eosinophils, immuno-
globulin E (IgE) and the more recently identiﬁed serum periostin, is
crucial. Periostin can be detected in peripheral blood [8] and has
been used as a biomarker to identify patients with Type 2 asthma or
who are most likely to beneﬁt from anti-IL-13 therapies [8e11].
In addition to furthering the understanding of the prognostic
value of individual biomarkers, there may be additional value in
determining their relationship with each other and the prognostic
value of various biomarker patterns. Currently, research consortia
such as U-BIOPRED (Unbiased Biomarkers in Prediction of Respi-
ratory Disease Outcomes) and SARP (Severe Asthma Research
Program) are addressing such issues in specialized academic cen-
tres. Investigations are needed to assess the utility of biomarkers in
a real-world setting over time.
The ARIETTA studywas, therefore, designed to assess a key set of
disease effectors or markers that are either available or in devel-
opment as clinically validated biomarkers, and examine their utility
over time in a real-world setting of severe asthma.
2. Materials and methods
2.1. Study design
ARIETTA is a prospective, single-arm, longitudinal, international,
non-interventional, multicentre study over 52 weeks in a cohort of
adult patients with severe asthma. Approximately 1200 patients
aged 18 years old will be enrolled, with the aim of at least 850
patients completing the 52-week study period. The study will enrol
patients with asthma who require a daily treatment regime with
inhaled corticosteroids (ICS) (total daily dose of 500 mg of ﬂuti-
casone propionate [FP] or equivalent) and a second controller. A
brief overview of the study scheme is shown in Fig. 1 with a
detailed schedule of the assessments in Table 1. Treatment received
by patients during the study will be determined by their treating
physicians' standard practices and discretion.
2.2. Study population
The study is recruiting patients 18 years of age with physician
diagnosed asthma, a pre-bronchodilator forced expiratory volume
in 1 second (FEV1) of 30e85%, a documented bronchodilator
response (12% improvement in FEV1 after bronchodilator use) or aFig. 1. Study sPC20 methacholine <8 mg, on current treatment with a total daily
dose of 500 mg of FP (or equivalent) and at least one additional
controller medication (long-acting beta-2 agonist, leukotriene re-
ceptor antagonist, long-acting muscarinic antagonist, theophylline
or oral corticosteroids) for a duration of 3 or more months prior to
baseline. Patients with an asthma exacerbation within 6 weeks
prior to baseline, current or ex-smokers (10 pack-years), treat-
ment with biologic therapy within 6 months prior to baseline and
patients who underwent bronchial thermoplasty are excluded (see
online repository for detailed information on inclusion and exclu-
sion criteria).
2.3. Study objectives
The primary objective for this study is to compare the rate of
asthma exacerbations between patients with low baseline periostin
levels (<50 ng/mL) and patients with high baseline periostin levels
(50 ng/mL), as measured by central laboratory testing, in order to
further assess periostin as a prognostic biomarker that can identify
at-risk asthma patients. The cut-off value of 50 ng/mL was chosen
based on previous phase II trials of the developmental anti-IL-13
agent lebrikizumab [9,12]. In these studies, the median value of
periostin for all patients (50 ng/mL) was used to deﬁne the cut-off
point between the high-periostin group (median value and higher)
and the low-periostin group (less than the median value) [9,12]. For
the purposes of this study, an asthma exacerbation is deﬁned (a) for
patients who are not onmaintenance oral corticosteroid therapy, as
new or increased asthma symptoms (including wheeze, cough,
dyspnoea, chest tightness, and/or night-time awakening due to
these symptoms) that lead to treatment with systemic corticoste-
roids (for at least 3 days) or to hospitalization/emergency depart-
ment visit with at least one dose of IV or IM corticosteroids (b) for
patients who are on maintenance oral corticosteroid therapy, as
new or increased asthma symptoms that lead to intensiﬁed treat-
ment with systemic corticosteroids 30 mg or 0.5 mg/kg for 3
consecutive days, or to hospitalization.
The main secondary and exploratory objectives of the study
include assessing the predicting ability of periostin (and other
biomarkers alone and in combination) for additional endpoints
including: relative change in pre-bronchodilator FEV1, time to ﬁrst
asthma exacerbation, change in FeNO, change in asthma-speciﬁc
health-related quality of life as assessed by the Mini Asthma
Quality of Life Questionnaire (MiniAQLQ), asthma-speciﬁc symp-
tom scores from baseline to Week 52 (ACT and ACQ-7) and time to
treatment failure (TTF). TTF is deﬁned as the ﬁrst occurrence of one
of the following events during the course of the study: asthma
exacerbation or clinically meaningful change in standard of care
(SoC) asthma treatment as reported by the Investigator andchematic.
Table 1
Schedule of assessments.
Week 1 13 26 39 52
Day (Assessment window) 1 91 (±28) 182 (±28) 273 (±28) 364 (±28)
Type of visits Baseline/Visit 1 Phone interview 1 Visit 2 Phone interview 2 Visit 3
Informed consent ✓
Study enrolment ✓
Bronchodilator response or methacholine bronchial challenge ✓
Pregnancy test ✓
Demographics ✓
Medical history ✓
Height and weight ✓ ✓
Medications ✓ ✓ ✓ ✓ ✓
Asthma exacerbations ✓ ✓ ✓ ✓ ✓
FeNO ✓ ✓ ✓
FEV1 ✓ ✓ ✓
Complete blood count ✓ ✓ ✓
Serum periostin and serum IgE ✓ ✓ ✓
Mini AQLQ ✓ ✓ ✓ ✓ ✓
ACQ-7 ✓ ✓ ✓ ✓ ✓
ACT ✓ ✓ ✓ ✓ ✓
ASUI ✓ ✓ ✓ ✓ ✓
WPAI-asthma ✓ ✓ ✓ ✓ ✓
Healthcare utilization ✓ ✓ ✓ ✓
Safety ✓ ✓ ✓ ✓ ✓
RCR sampling (optional) ✓ ✓
Abbreviations: ACQ-7: Asthma Control Questionnaire-7; ACT: Asthma Control Test; ASUI: Asthma Symptom Utility Index; FeNO: fractional exhaled nitric oxide; FEV1: forced
expiratory volume in 1 second; IgE: immunoglobulin E; Mini AQLQ: Mini Asthma Quality of Life Questionnaire; RCR: Roche Clinical Repository; WPAI-Asthma: Work Pro-
ductivity and Activity Impairment Questionnaire-Asthma.
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be available in the local language as required. FEV1 will be
measured according to local standard techniques for spirometry
and at sites where FeNO measurement is the SoC, FeNO will be
measured using the local standard device and techniques as
available.
The prognostic value of other established biomarkers and other
predictive factors assessed at baseline (e.g. blood eosinophil counts,
FeNO, serum IgE and history of asthma exacerbations over the 12
months prior to Visit 1) and their composite measures with base-
line periostin with respect to the rate of asthma exacerbations
during the studywill also be assessed. To determine the importance
of baseline periostin levels in different subgroups of patients, the
prognostic valuewith respect to the rate of asthma exacerbations in
patients receiving GINA step 4 treatment including 500e1000 mg FP
or >1000 mg FP, GINA step 5 treatment and also in geographical and
ethnic subgroups of patients will be investigated.
The association between biomarkers and clinically meaningful
changes in SoC medication and healthcare utilization, as reported
by the investigator, will be evaluated during the study. Further-
more, the association between biomarker levels measured at
baseline and the rate of urgent asthma-related healthcare utiliza-
tion (deﬁned as hospitalizations, emergency department visits and
acute care visits due to asthma and asthma-related symptoms) over
the study period will be examined. All medications taken during
the study period will be recorded, including medication type,
generic name, start and stop date, dose and administration
schedule.
Variation between periostin levels, blood eosinophil counts and
serum IgE levels as measured by the central laboratory versus
regional reference (periostin) or local (blood eosinophils, serum
IgE) laboratories will be assessed (see online repository for detailed
information on biomarker assessment).
The safety endpoints include the assessment of the frequency
and severity of adverse events related to the study procedures,
serious adverse events, and medical events of special interest
(anaphylaxis/anaphylactoid/hypersensitivity reaction, infection,
malignant neoplasm, diabetes mellitus, cataract, dental operations,pregnancies or bone fracture) over the study period.
2.4. Statistical methods
For the primary efﬁcacy analysis, the rate of asthma exacerba-
tions will be compared between periostin-high and periostin-low
groups (determined by central laboratory testing) by means of a
Poisson regression model with over-dispersion. For each group, the
unadjusted rate of asthma exacerbations will be estimated by the
total number of exacerbations observed during the 52-week period
divided by the total patient-weeks at risk in each periostin group.
The analysis will be based on the observed exacerbations, with no
imputation for early discontinuations. A patient's time at risk will
be computed and used as an offset term in the model. Rates of
asthma exacerbations and associated 95% conﬁdence intervals will
be estimated for each periostin group using the aforementioned
Poisson regression model. The relative difference in the exacerba-
tion rate (between periostin-high and periostin-low groups) will be
estimated by the exponential periostin group regression coefﬁ-
cient, and the periostin group coefﬁcient from the Poisson regres-
sion model will be used to test the difference in exacerbation rates
by use of a Likelihood Ratio test statistic. The hypothesis test for the
primary endpoint will be two-sided and performed at a signiﬁcance
level of 0.05.
For secondary endpoints the Poisson regression model with
over-dispersion will also be used to evaluate the relationship be-
tween other biomarkers and exacerbation rates as well as for
assessing effect on exacerbation rates in certain patient subgroups.
Changes over time in biomarkers and lung performance measures
(FEV1) will be modelled versus time and baseline periostin (high
versus low) covariates, by means of a generalized linear mixed-
effects model.
The effect of baseline periostin (high versus low) on time to ﬁrst
asthma exacerbation and TTF will be analysed using Cox propor-
tional hazards regression models, while clinically meaningful
changes in SoC asthma treatment and changes in rate of urgent
asthma-related healthcare utilization will be summarized using
descriptive statistics by baseline periostin groups.
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serum IgE and FeNO, each measured at baseline and at each sub-
sequent visit, will be calculated by using Spearman's correlation
coefﬁcient. A method comparison between biomarkers measured
by central laboratory testing and by regional reference/local labo-
ratory testing will be performed using the Passing-Bablok regres-
sion for evaluating the extent of the constant and proportional bias.
Further measures of association/correlation between selected
biomarkers or risk factors (e.g. blood eosinophil count, FeNO, serum
IgE, history of asthma exacerbation) and rate of asthma exacerba-
tions, FEV1, time to ﬁrst treatment failure (time to ﬁrst asthma
exacerbation or clinically meaningful changes in SoC asthma
treatment), asthma-related quality of life (as assessed by the min-
iAQLQ) and asthma-related healthcare utilization will be explored
using relevant descriptive statistics and similar statistical models,
as described for primary and secondary endpoint analyses. Further
details will be pre-speciﬁed in the statistical analysis plan. The
number of serious adverse events, medical events of special inter-
est, and study assessment-related adverse events will be summa-
rized overall and by patients with low and high baseline periostin.
Asthma-related medications and other (non-study condition)
medications recorded during the study will be summarized by
frequency tables, overall and by baseline periostin groups.
2.5. Determination of sample size
The study is powered to detect a clinically meaningful relative
difference in rate of exacerbations in the periostin-high group
versus the periostin-low group. Assuming 50% of the enrolled pa-
tients will have high periostin levels and 50% low periostin levels,
with 849 patients completing 52 weeks, the study will provide at
least 80% power to detect an increase in rate of asthma exacerba-
tions by 35% (i.e. reject the null hypothesis), with an assumption of
average rate of 0.637 exacerbations per patient in the periostin-low
group (as determined by the EXTRA study [13]) over a 52-week
period. Assuming a dropout rate of 30%, approximately 1213 pa-
tients will be required to be enrolled in the study.
3. Discussion
Asthma is a complex disorder and several phenotypes have
already been identiﬁed based on observed variability in the clinical
course of disease. This fact may have important implications for
treatment [3e5] and capability to identify patients who may
beneﬁt from targeted treatment and thus may have a considerable
impact on the future of asthma care. In a real-world setting for
patients with severe asthma, the ARIETTA study aims to enhance
our understanding of the prognostic value of existing and emerging
biomarkers in routine clinical practice. The unique strengths of this
study include the ﬂexibility in the inclusion criteria in order to
capture a broad range of severe asthma patients who are treated
with ICS therapy (500 mg of FP equivalents) and at least a second
controller. These ICS doses are comparable with ﬁndings from the
UK National Difﬁcult Asthma registry where an average ICS use of
2000 mg beclometasone dipropionate equivalents (range
1000e2000 mg) along with short-acting beta-2 agonist was
observed [14]. Furthermore, during the study period patients will
be evaluated and treated according to the investigator's standard
practice and discretion.
The utility of biomarkers in asthma for predicting future exac-
erbations, response to treatment or lung function decline is a topic
of growing interest [15e21]. The primary aim of this study is to
further assess the prognostic value of periostin in relation to risk of
future asthma exacerbations. To date, ﬁndings on this speciﬁc
endpoint have been mainly studied in structured clinical trials. Arecently reported phase IIb trial with lebrikizumab demonstrated a
higher incidence of future exacerbations in placebo-treated pa-
tients with high (>50 ng/mL) serum periostin at baseline compared
with placebo-treated patients with low baseline serum periostin
levels [12]. ARIETTA is speciﬁcally designed and statistically pow-
ered to investigate differences in exacerbation rates between those
with high or low periostin levels in a setting more closely resem-
bling real-world practice where the choice of asthma treatment is
not governed by an interventional clinical trial. Considering other
biomarkers in addition to high levels of serum periostin, blood
eosinophils and FeNO were also prognostic for increases in severe
asthma exacerbations in the placebo arm of another large clinical
trial with omalizumab [13]. Furthermore, in that trial, the treat-
ment effect of omalizumab in reducing asthma exacerbation was
more pronounced with all three high-baseline-biomarker sub-
groups (FeNO, blood eosinophils and serum periostin) compared
with the low-biomarker subgroups e a result that reﬂects another
study ﬁnding demonstrating no effect of omalizumab in
eosinophil-low (<300 cells/mL at baseline) patients [22].
The utility of single biomarkers has been explored in several
studies. Sputum eosinophil-guided treatment was shown to reduce
asthma exacerbations in moderate-to-severe patients (compared
with guideline-based management) [15] and blood eosinophil
count has been used to assess the response to ICS tapering [23]. In
contrast, a meta-analysis of studies using FeNO to tailor ICS treat-
ment did not show any beneﬁt in improving clinical symptoms or
reducing the rate of asthma exacerbations [24]. The present study
will be able to provide further information regarding the potential
utility of such biomarkers, including FeNO, as a prognostic
biomarker. In terms of predicting lung function dynamics, a recent
study reported an association between elevated serum periostin
levels and a decline in FEV1 in patients with asthma [20]. In another
longitudinal trial, high periostin levels were identiﬁed to be an
independent risk factor for FEV1 deterioration in asthmatics [25].
Given the fragmented nature of these assessments of single bio-
markers, the ARIETTA study will therefore help to establish the
prognostic utility and correlation of all relevant biomarkers on lung
function over time in a real-world setting, although the duration of
follow-up (1 year) may not be long enough to determine this with
great certainty.
It is noteworthy, that many of the more researched asthma
biomarkers are related to pathways of Type 2 inﬂammation,
mediated by Type 2 cytokines. For example, all of the biomarkers
assessed here can be linked to Type 2-dependent mechanisms.
Periostin is a matricellular protein that is induced by IL-13 in
bronchial epithelial cells and ﬁbroblasts. It can be rapidly secreted
from the basolateral side into the subepithelial space where it gains
access to the vascular plexus and can thus be detected in peripheral
blood [8,9,26,27]. Eosinophils are inﬂammatory cells that may be
present in increased numbers in the airways and blood of patients
with asthma [28] and their maturation, mobilization and recruit-
ment to areas of inﬂammation are controlled by the Type 2 cyto-
kines IL-5 and IL-13 [29e32]. FeNO is produced by nitric oxide
synthase, the expression of which is driven by IL-13 and IL-4
[33e35]. Consequently, these biomarkers will most likely display
a certain degree of overlap since Type 2 cytokines are expected to
be secreted in an interrelated way, rather than in a singular mode.
This study will capture data on how extensive and stable this
overlap might be over time, and aims to contribute to our under-
standing on how best to interpret the range of biomarkers in the
context of the real-world clinical picture and beyond the selection
bias that can be observed in clinical intervention trials. The ARIETTA
study also offers the opportunity to investigate the potential value
of utilizing a composite biomarker in the clinical assessment of
patients with asthma. The RASP-UK study group is examining the
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ophils as a composite biomarker to predict exacerbation risk in the
placebo arms of clinical trials conducted with lebrikizumab and
with omalizumab in patients treated with at least 500 mg FP and a
second controller. Preliminary results demonstrated that, individ-
ually, these biomarkers are all correlated with exacerbation risk,
but using the three biomarkers in a ‘composite’ score further
differentiated patients on the basis of exacerbation rate [36].
Adherence to asthma therapy is of considerable interest and in
an interventional clinical trial, rates of treatment adherence are
often as high as 90% [37e39]. This differs dramatically from real-life
clinical practice where adherence to the pharmacological treat-
ments for asthma is well known to be low, and approximately half
of those prescribed long-term treatment fail to adhere, at least part
of the time [40]. In this real-world study, patients with moderate-
to-severe asthma will be treated according to the Investigator's
routine clinical practices and the study design ensures that beyond
the verbal afﬁrmation between the study participant and the
investigator at the start of the study, no interventions will be
included. Clinic visits at the start of the study, Week 26 and Week
52, and telephone interviews at Week 13 and Week 39 allow the
longitudinal stability and relationship between key biomarkers to
be studied in relation to clinical parameters in the real-world sit-
uation. Withdrawal rates may be a challenge for a long-term, non-
interventional study, such as ARIETTA. To address this factor, an
allowance for a 30% drop-out rate has been built into the study
design. However, it must also be considered that allowing patients
to change treatment during the study, according to the in-
vestigator's standard practice and discretion, should limit with-
drawal rates. Furthermore, the telephone interviews at Weeks 13
and 39 aim to improve patient retention as well as remind the
participants to answer the patient-reported outcome (PRO) forms.
A unique feature of this study is the opportunity to compare the
value of assessing biomarkers at central and regional/local labora-
tories e identifying if variability is increased between different
laboratories as the impact of testing locally versus at a central
laboratory is not known on these outcomes. This will greatly help to
put into perspective the large number of current randomized
clinical trials and how their centrally read biomarker data can be
translated into routine clinical practice. In particular it may help
determine the most reliable method of eosinophil testing. The
variability of airway eosinophilia typically means that diagnostic
accuracy is inﬂuenced by clinical setting, context and prevalence
[41]. This example highlights the necessity of implementing
harmonized procedures for the assessment of biomarkers. Local
reference laboratories perform testing based on local procedures
and practices, which may make it challenging to correlate and
standardize results across sites. Large studies using central study
analysis use a protocol-deﬁned analysis that is harmonized across
multiple study sites. The comparison of local vs central analysis of
eosinophils has not previously been investigated and this study
may provide some useful insights.
Finally, it is also hoped that the distribution of biomarkers
among subgroups of asthma patients can be investigated during
this study. It is unclear from the literature whether any of the
biomarkers investigated reliably correlate with severity or symp-
toms of asthma.4. Conclusions
In summary, the unique design of the ARIETTA study aims to
address many unanswered questions regarding biomarkers in se-
vere asthma and their relationship to each other, to future asthma
events and to control in a real-world setting.Acknowledgements
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